INTERBLEED: Design of an International Study of Risk Factors for Gastrointestinal Bleeding and Cardiovascular Events After Gastrointestinal Bleeding.

Autor:	Bosch J; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.; School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada., Moayyedi P; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Alings M; Amphia Ziekenhuis, Breda, The Netherlands., Avezum A Jr; International Research Centre, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Bangdiwala SI; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Barkun A; Research Institute of the McGill University Health Centre/Institut de recherche du Centre universitaire de santé McGill, Montreal, Quebec, Canada., Cassella F; Fundación Sanatorio Güemes, Buenos Aires, Argentina., Marchi da Rocha A; Sociedade Campineira de Educação e Instrução, São Paulo, Brazil., Duzen I; Gaziantep Üniversitesi Tıp Fakültesi Şahinbey Eğitim ve Araştırma Hastanesi, Gaziantep, Turkey., Enns R; University of British Columbia, Vancouver, British Columbia, Canada., Forbes N; Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada., Hamilton L; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Islam S; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada., Kilickap M; Cardiology Department, Ankara University School of Medicine, Ankara, Turkey., Kruger P; Fiona Stanley Hospital, Perth, Western Australia, Austrailia., Liang Y; Emergency Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Nicolau JC; Instituto do Coração do Hospital das Clincias da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil., Nunes R; Clinical Cardiology and Cardio-Oncology, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., O'Donnell M; College of Medicine, Nursing and Health Sciences, University of Galway, Galway, Ireland., Oliveira G; International Research Centre, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Rey A; Medicina Interna, Centro de Educación Médica e Investigaciones Clínicas (CEMIC), Buenos Aires, Argentina., Sun Y; China-Japan Friendship Hospital, Beijing, China., Vanassche T; KU Leuven Department of Cardiovascular Sciences, Leuven, Belgium., Verhamme P; KU Leuven Department of Cardiovascular Sciences, Leuven, Belgium., Walsh M; Department of Medicine, McMaster University, Hamilton, Ontario, Canada.; Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada., Wang Z; Beijing Traditional Chinese Medicine Hospital, Beijing, China., Wu C; Research Transition Facility, University of Alberta, Edmonton, Alberta, Canada., Zhao L; Fu Xing Hospital, Beijing, China., Zhu J; Emergency Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Eikelboom JW; Population Health Research Institute, McMaster University, Hamilton, Ontario, Canada.
Jazyk:	angličtina
Zdroj:	CJC open [CJC Open] 2022 Aug 10; Vol. 4 (11), pp. 996-1005. Date of Electronic Publication: 2022 Aug 10 (Print Publication: 2022).
DOI:	10.1016/j.cjco.2022.08.002
Abstrakt:	Background: Bleeding is the most common adverse event in those with cardiovascular (CV) disease receiving antithrombotic therapy, and it most commonly occurs in the gastrointestinal (GI) tract. Clinicians often dismiss bleeding as an adverse event that is reversible with effective antithrombotic therapy, but bleeding is associated with substantial morbidity and mortality, most likely mediated through an increased risk of CV events. Reducing the burden of bleeding requires knowledge of the potentially modifiable risk factors for bleeding and the potentially modifiable risk factors for adverse outcomes after bleeding. Methods: INTERBLEED is an international, multicentre, 2-component, observational study, with an incident case-control study examining the risk factors for GI bleeding, and a prospective cohort study of risk factors for CV events after GI bleeding. Cases either have CV disease and present to the hospital with GI bleeding or develop GI bleeding during hospitalization. Controls have CV disease, but no history of GI bleeding. We use a questionnaire to obtain detailed information on known and potential risk factors for GI bleeding and for CV events and outcomes after bleeding. We obtain CV and anthropometric measurements, perform functional and cognitive assessments, and follow participants at 3 months and 12 months. Results: As of April 1, 2022, the study is ongoing in 10 countries at 31 centres and has recruited 2407 cases and 1478 controls. Conclusions: Knowledge of risk factors for bleeding, and risk factors for CV events and functional decline after bleeding, will help develop strategies to prevent bleeding and subsequent complications. (© 2022 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu